Michael R. Zalutsky
#138,120
Most Influential Person Now
Michael R. Zalutsky's AcademicInfluence.com Rankings
Michael R. Zalutskychemistry Degrees
Chemistry
#3431
World Rank
#4449
Historical Rank
Organic Chemistry
#543
World Rank
#627
Historical Rank
Michael R. Zalutskybiology Degrees
Biology
#9598
World Rank
#12822
Historical Rank
Molecular Biology
#1334
World Rank
#1361
Historical Rank
Biochemistry
#1480
World Rank
#1607
Historical Rank
Download Badge
Chemistry Biology
Michael R. Zalutsky's Degrees
- Bachelors Chemistry University of California, Berkeley
- PhD Chemistry University of California, Berkeley
Why Is Michael R. Zalutsky Influential?
(Suggest an Edit or Addition)Michael R. Zalutsky's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. (1990) (395)
- Pinhole collimation for ultra-high-resolution, small-field-of-view SPECT. (1994) (336)
- Clinical Experience with α-Particle–Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6 (2007) (320)
- Molecular Imaging of Hypoxia (2011) (277)
- Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. (2002) (262)
- Progress Report of a Phase I Study of the Intracerebral Microinfusion of a Recombinant Chimeric Protein Composed of Transforming Growth Factor (TGF)-α and a Mutated form of the Pseudomonas Exotoxin Termed PE-38 (TP-38) for the Treatment of Malignant Brain Tumors (2003) (240)
- Radiolocalization of human mammary tumors in athymic mice by a monoclonal antibody. (1983) (238)
- A Plasmonic Gold Nanostar Theranostic Probe for In Vivo Tumor Imaging and Photothermal Therapy (2015) (230)
- Targeting a genetically engineered elastin-like polypeptide to solid tumors by local hyperthermia. (2001) (222)
- Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. (1998) (195)
- Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. (2008) (188)
- Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. (2006) (186)
- The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. (1998) (185)
- Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy. (2000) (180)
- A method for the radiohalogenation of proteins resulting in decreased thyroid uptake of radioiodine. (1987) (171)
- Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. (1989) (165)
- A thermally responsive biopolymer for intra-articular drug delivery. (2006) (164)
- In situ growth of a stoichiometric PEG-like conjugate at a protein's N-terminus with significantly improved pharmacokinetics (2009) (152)
- In situ growth of a PEG-like polymer from the C terminus of an intein fusion protein improves pharmacokinetics and tumor accumulation (2010) (141)
- Tumor accumulation, degradation and pharmacokinetics of elastin-like polypeptides in nude mice. (2006) (139)
- Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity. (1989) (137)
- Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides. (2006) (134)
- Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. (2000) (132)
- Copper signaling axis as a target for prostate cancer therapeutics. (2014) (123)
- Synthesis of N-succinimidyl 4-[18F]fluorobenzoate, an agent for labeling proteins and peptides with 18F (2006) (119)
- Astatine-211: production and availability. (2011) (115)
- Radioimmunotherapy with alpha-particle emitting radionuclides. (2004) (109)
- Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. (1995) (109)
- Radioimmunotherapy with α-Particle Emitting Radioimmunoconjugates (1996) (108)
- Labeling proteins with fluorine-18 using N-succinimidyl 4-[18F]fluorobenzoate. (1992) (104)
- Targeted α-Particle Radiotherapy with 211At-labeled Monoclonal Antibodies (2007) (102)
- Interaction of monoclonal antibodies with cell surface antigens of human ovarian carcinomas. (1984) (100)
- Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl 3-(tri-n-butylstannyl)benzoate. (1989) (99)
- Astatination of proteins using an N-succinimidyl tri-n-butylstannyl benzoate intermediate. (1988) (98)
- Therapeutic efficacy of antiglioma mesenchymal extracellular matrix 131I-radiolabeled murine monoclonal antibody in a human glioma xenograft model. (1988) (98)
- Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. (1996) (96)
- (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy (2016) (96)
- A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. (2008) (95)
- Targeted therapy using alpha emitters. (1996) (93)
- Reagents for astatination of biomolecules: comparison of the in vivo distribution and stability of some radioiodinated/astatinated benzamidyl and nido-carboranyl compounds. (2004) (92)
- Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas. (2010) (92)
- Protein polymer hydrogels by in situ, rapid and reversible self-gelation. (2012) (92)
- Injectable intratumoral depot of thermally responsive polypeptide-radionuclide conjugates delays tumor progression in a mouse model. (2010) (88)
- 131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment (2017) (88)
- Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. (2005) (87)
- No-carrier-added synthesis of meta-[131I]iodobenzylguanidine. (1993) (87)
- Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. (2003) (85)
- Enhanced delivery of a monoclonal antibody F(ab')2 fragment to subcutaneous human glioma xenografts using local hyperthermia. (1990) (84)
- Evaluation of an internal cyclotron target for the production of 211At via the 209Bi (α,2n)211At reaction (1996) (84)
- Comparative tissue distribution in mice of the alpha-emitter 211At and 131I as labels of a monoclonal antibody and F(ab')2 fragment. (1990) (82)
- Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody. (2013) (81)
- Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody. (2000) (80)
- Phase I studies of treatment of malignant gliomas and neoplastic meningitis with131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab′)2-a preliminary report (2005) (80)
- Improved synthesis of N-succinimidyl 4-[18F]fluorobenzoate and its application to the labeling of a monoclonal antibody fragment. (1994) (79)
- 211At radiocolloid therapy: further observations and comparison with radiocolloids of 32P, 165Dy, and 90Y. (1984) (77)
- Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6. (1988) (76)
- Radioimmunotherapy of Neoplastic Meningitis in Rats Using an α-Particle-emitting Immunoconjugate (1994) (73)
- Radiohalogenation of a monoclonal antibody using an N-succinimidyl 3-(tri-n-butylstannyl)benzoate intermediate. (1988) (73)
- High-Level Production of α-Particle–Emitting 211At and Preparation of 211At-Labeled Antibodies for Clinical Use (2001) (73)
- Improved Tumor Targeting of Anti-HER2 Nanobody Through N-Succinimidyl 4-Guanidinomethyl-3-Iodobenzoate Radiolabeling (2014) (72)
- Colocalization of Gadolinium-Diethylene Triamine Pentaacetic Acid With High-Molecular-Weight Molecules After Intracerebral Convection-Enhanced Delivery in Humans (2011) (69)
- Synthesis of radioiodinated N-succinimidyl iodobenzoate: optimization for use in antibody labelling. (1989) (69)
- Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate. (1996) (68)
- Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients (2007) (68)
- Monoclonal antibody and F(ab')2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration. (1990) (67)
- Pharmacokinetics of radiolabeled monoclonal antibody B6.2 in patients with metastatic breast cancer. (1986) (66)
- Uptake mechanisms of meta-[123I]iodobenzylguanidine in isolated rat heart. (1995) (66)
- Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. (2000) (65)
- Fluorine-18 labeling of monoclonal antibodies and fragments with preservation of immunoreactivity. (1991) (64)
- N-succinimidyl 5-(trialkylstannyl)-3-pyridinecarboxylates: a new class of reagents for protein radioiodination. (1991) (63)
- Current status of therapy of solid tumors: brain tumor therapy. (2005) (63)
- Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate. (1997) (62)
- 125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts. (1999) (61)
- Applications of 211At and 223Ra in targeted alpha-particle radiotherapy. (2011) (61)
- Treatment of rheumatoid synovitis of the knee with intraarticular injection of dysprosium 165-ferric hydroxide macroaggregates. (1986) (60)
- Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET (2016) (58)
- In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction. (2006) (58)
- The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro. (1998) (57)
- Distribution and dosimetry of I-123-labeled monoclonal antibody 81C6 in patients with anaplastic glioma. (1993) (56)
- Blocking [211At]astatide accumulation in normal tissues: preliminary evaluation of seven potential compounds. (1998) (56)
- Targeted radiotherapy of brain tumours (2004) (56)
- 1-(m-[211At]astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation. (1992) (55)
- Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis. (1990) (54)
- Astatine Radiopharmaceuticals: Prospects and Problems. (2008) (54)
- 211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation. (1999) (54)
- Comparative localization of murine monoclonal antibody Me1-14 F(ab')2 fragment and whole IgG2a in human glioma xenografts. (1988) (54)
- Enhanced binding and inertness to dehalogenation of alpha-melanotropic peptides labeled using N-succinimidyl 3-iodobenzoate. (1996) (53)
- Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells. (2013) (51)
- Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate. (1999) (51)
- Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG. (1995) (50)
- Preparation of N-succinimidyl 3-[*I]iodobenzoate: an agent for the indirect radioiodination of proteins (2006) (50)
- Protein radiohalogenation: observations on the design of N-succinimidyl ester acylation agents. (1990) (50)
- Local hyperthermia improves uptake of a chimeric monoclonal antibody in a subcutaneous xenograft model. (1997) (50)
- Research and clinical potential of receptor based radiopharmaceuticals. (1985) (49)
- Brachytherapy using injectable seeds that are self-assembled from genetically encoded polypeptides in situ. (2012) (49)
- Fluorine-18-labeled [Nle4,d-Phe7]-α-MSH, an α-melanocyte stimulating hormone analogue (1997) (49)
- Preparation of a biologically stable and immunogenically competent astatinated protein. (1977) (48)
- Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies. (2007) (48)
- Cytotoxicity of α-particle-emitting m-[211At]astatobenzylguanidine on human neuroblastoma cells (1994) (48)
- Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions. (1998) (47)
- Prostate-Specific Membrane Antigen–Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer (2016) (47)
- A polar substituent-containing acylation agent for the radioiodination of internalizing monoclonal antibodies: N-succinimidyl 4-guanidinomethyl-3-[131I]iodobenzoate ([131I]SGMIB). (2001) (47)
- Monoclonal antibodies for brain tumour treatment (2004) (47)
- Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. (2006) (46)
- Engineered modular recombinant transporters: application of new platform for targeted radiotherapeutic agents to alpha-particle emitting 211 At. (2008) (46)
- Measuring astatine-211 distributions with SPECT. (1993) (46)
- Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate. (1997) (46)
- A local hyperthermia treatment which enhances antibody uptake in a glioma xenograft model does not affect tumour interstitial fluid pressure. (1997) (46)
- Fluorine-18-labeled monoclonal antibody fragments: a potential approach for combining radioimmunoscintigraphy and positron emission tomography. (1992) (45)
- PET imaging of osteosarcoma in dogs using a fluorine-18-labeled monoclonal antibody Fab fragment. (1994) (45)
- (4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography. (1994) (45)
- In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parent. (1997) (45)
- Injectable polypeptide micelles that form radiation crosslinked hydrogels in situ for intratumoral radiotherapy. (2016) (45)
- Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein tenascin (1994) (45)
- Hyperthermic modulation of radiolabelled antibody uptake in a human glioma xenograft and normal tissues. (1995) (44)
- Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors. (1999) (44)
- A kit method for the high level synthesis of [211At]MABG. (2007) (44)
- Comparative localization of glioma-reactive monoclonal antibodies in vivo in an athymic mouse human glioma xenograft model (1987) (44)
- Sodium-iodide symporter (NIS)-mediated accumulation of [(211)At]astatide in NIS-transfected human cancer cells. (2002) (43)
- Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation. (2018) (43)
- Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma. (1995) (41)
- Survival and DNA damage in Chinese hamster V79 cells exposed to alpha particles emitted by DNA-incorporated astatine-211. (1998) (40)
- Synthesis and preliminary evaluation of para- and meta-[18F]fluorobenzylguanidine. (1994) (40)
- Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy (2020) (40)
- Modular nanotransporters: a multipurpose in vivo working platform for targeted drug delivery (2012) (40)
- In vitro cytotoxicity of (211)at-astatide and (131)I-iodide to glioma tumor cells expressing the sodium/iodide symporter. (2003) (39)
- Radiolabeling and in vitro evaluation of (67)Ga-NOTA-modular nanotransporter--a potential Auger electron emitting EGFR-targeted radiotherapeutic. (2014) (39)
- Imaging of pheochromocytoma in 2 dogs using p-[18F] fluorobenzylguanidine. (2002) (39)
- Comparison of monoclonal antibody delivery to intracranial glioma xenografts by intravenous and intracarotid administration. (1987) (38)
- Preparation of 5-[131I]iodo- and 5-[211At]astato-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) uracil by a halodestannylation reaction. (1998) (38)
- Tracking the in vivo fate of recombinant polypeptides by isotopic labeling. (2006) (38)
- 5-[211At]Astato-2′-deoxyuridine, an α-Particle-emitting Endoradiotherapeutic Agent Undergoing DNA Incorporation (1996) (38)
- Targeted alpha-particle therapy of microscopic disease: Providing a further rationale for clinical investigation. (2006) (38)
- Synovectomy of the rheumatoid knee using intra-articular injection of dysprosium-165-ferric hydroxide macroaggregates. (1987) (37)
- Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma. (2004) (37)
- Quantitation of 211At in small volumes for evaluation of targeted radiotherapy in animal models. (1995) (37)
- Meta‐[211AT]astatobenzylguanidine: Further evaluation of a potential therapeutic agent (1994) (36)
- Microdosimetric analysis of alpha-particle-emitting targeted radiotherapeutics using histological images. (2003) (36)
- N-succinimidyl 3-[211At]astato-4-guanidinomethylbenzoate: an acylation agent for labeling internalizing antibodies with alpha-particle emitting 211At. (2003) (36)
- Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate. (2002) (35)
- Synthesis of N-succinimidyl 4-guanidinomethyl-3-[*I]iodobenzoate: a radio-iodination agent for labeling internalizing proteins and peptides (2007) (35)
- Potential of Immuno–Positron Emission Tomography for Tumor Imaging and Immunotherapy Planning (2006) (34)
- Modular nanotransporters: a versatile approach for enhancing nuclear delivery and cytotoxicity of Auger electron-emitting 125I (2012) (34)
- Fluorine-18 labeled chemotactic peptides: a potential approach for the PET imaging of bacterial infection. (1995) (33)
- 18F-EF5 PET Imaging as an Early Response Biomarker for the Hypoxia-Activated Prodrug SN30000 Combined with Radiation Treatment in a Non–Small Cell Lung Cancer Xenograft Model (2013) (33)
- Radioiodinated B6.2 monoclonal antibody: further characterization of a potential radiopharmaceutical for the identification of breast tumors. (1985) (33)
- Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution. (1999) (33)
- Evaluation of meta-[211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model. (1996) (32)
- Preparation of Rh[16aneS4-diol](211)At and Ir[16aneS4-diol](211)At complexes as potential precursors for astatine radiopharmaceuticals. Part I: Synthesis. (2008) (32)
- Microdosimetry of astatine-211 using histological images: application to bone marrow. (1997) (32)
- Monoclonal antibodies to tissue-specific cell surface antigens. I. Characterization of an antibody to a prostate tissue antigen. (1984) (32)
- Antibodies in Radiodiagnosis and Therapy (1988) (31)
- Synthesis and preliminary biological evaluation of (3-iodobenzoyl)norbiotinamide and ((5-iodo-3-pyridinyl)carbonyl)norbiotinamide: two radioiodinated biotin conjugates with improved stability. (1997) (31)
- Radioiodination of antibodies via N-succinimidyl 2,4-dimethoxy-3-(trialkylstannyl)benzoates. (1990) (30)
- Radiopharmaceutical Chemistry of Targeted Radiotherapeutics, Part 3: α-Particle–Induced Radiolytic Effects on the Chemical Behavior of 211At (2007) (30)
- Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts. (2003) (30)
- Improved therapeutic efficacy of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate. (1991) (30)
- Radioimmunotherapy of intracerebral human glioma xenografts with 131I-labeled F(ab')2 fragments of monoclonal antibody Mel-14. (1990) (30)
- Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands. (2007) (30)
- N-succinimidyl 3-[(131)I]iodo-4-phosphonomethylbenzoate ([(131)I]SIPMB), a negatively charged substituent-bearing acylation agent for the radioiodination of peptides and mAbs. (2003) (30)
- Spatiotemporally photoradiation-controlled intratumoral depot for combination of brachytherapy and photodynamic therapy for solid tumor. (2016) (30)
- Astatine-211-labeled biotin conjugates resistant to biotinidase for use in pretargeted radioimmunotherapy. (1998) (29)
- Radioiodinated antibody targeting of the HER-2/neu oncoprotein. (1997) (29)
- Targeted Radiotherapy: Microgray Doses and the Bystander Effect (2007) (29)
- Rhenium heptasulfide: a potential carrier system for radiation synovectomy. (1990) (29)
- High-level production of alpha-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use. (2001) (29)
- Wet harvesting of no-carrier-added 211At from an irradiated 209Bi target for radiopharmaceutical applications (2004) (28)
- Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 2: radiolytic effects of 211At alpha-particles influence N-succinimidyl 3-211AT-astatobenzoate synthesis. (2005) (28)
- Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors. (2012) (28)
- Chimeric anti-tenascin antibody 81C6: increased tumor localization compared with its murine parent. (1996) (28)
- Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate. (1994) (27)
- N-succinimidyl 4-methyl-3-(tri-n-butylstannyl)benzoate: synthesis and potential utility for the radioiodination of monoclonal antibodies. (1993) (27)
- Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis. (2002) (27)
- Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands. (2010) (26)
- Radiation synovectomy with 165Dy-FHMA: lymph node uptake and radiation dosimetry calculations. (1986) (26)
- Radioiodine and 211At-labeled guanidinomethyl halobenzoyl octreotate conjugates: potential peptide radiotherapeutics for somatostatin receptor-positive cancers (2004) (26)
- Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysis. (1999) (26)
- Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation. (2018) (25)
- Catabolism of radioiodinated murine monoclonal antibody F(ab')2 fragment labeled using N-succinimidyl 3-iodobenzoate and Iodogen methods. (1995) (25)
- Recombinant single‐chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas (2010) (24)
- Radiopharmaceutical chemistry of targeted radiotherapeutics, part 1: effects of solvent on the degradation of radiohalogenation precursors by 211At alpha-particles. (2005) (24)
- Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligands. (2009) (24)
- Nepsilon-(3-[*I]Iodobenzoyl)-Lys5-Nalpha-maleimido-Gly1-GEEEK ([*I]IB-Mal-D-GEEEK): a radioiodinated prosthetic group containing negatively charged D-glutamates for labeling internalizing monoclonal antibodies. (2006) (24)
- Preparation, cytotoxicity, and in vivo antitumor efficacy of 111In-labeled modular nanotransporters (2017) (23)
- Uptake and retention kinetics of para-fluorine-18-fluorobenzylguanidine in isolated rat heart. (1996) (23)
- Radioimmunotherapy of breast cancer xenografts with monoclonal antibody ICR12 against c-erbB2 p185: comparison of iodogen and N-succinimidyl 4-methyl-3-(tri-n-butylstannyl)benzoate radioiodination methods. (1995) (23)
- An Efficient Method for Labeling Single Domain Antibody Fragments with 18F Using Tetrazine- Trans-Cyclooctene Ligation and a Renal Brush Border Enzyme-Cleavable Linker. (2018) (23)
- No-carrier-added meta-[123I]iodobenzylguanidine: synthesis and preliminary evaluation. (1995) (23)
- A NEW ROUTE TO GUANIDINES FROM BROMOALKANES (1997) (23)
- The localisation of radiolabelled murine monoclonal antibody 81C6 and its Fab fragment in human glioma xenografts in athymic mice. (1988) (22)
- Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates. (1996) (22)
- Radiolabeled guanine derivatives for the in vivo mapping of O(6)-alkylguanine-DNA alkyltransferase: 6-(4-[(18)F]Fluoro-benzyloxy)-9H-purin-2-ylamine and 6-(3-[(131)I]Iodo-benzyloxy)-9H-purin-2-ylamine. (2000) (22)
- Long term response in a patient with neoplastic meningitis secondary to melanoma treated with 131I‐radiolabeled antichondroitin proteoglycan sulfate Mel‐14 F(ab′)2 (2001) (22)
- Preclinical evaluation of no-carrier-added [131I]meta-iodobenzyl guanidine, for the treatment of tumours transfected with the noradrenaline transporter gene (2004) (21)
- Synthesis and evaluation of glycosylated octreotate analogues labeled with radioiodine and 211At via a tin precursor. (2006) (21)
- Fluorine-18-labeled [Nle4,D-Phe7]-alpha-MSH, an alpha-melanocyte stimulating hormone analogue. (1997) (21)
- Enhanced tumour uptake of radiolabelled antibodies by hyperthermia: Part I: Timing of injection relative to hyperthermia (2005) (21)
- Imaging drug resistance with radiolabeled molecules. (2004) (21)
- Radiotoxicity of systematically administered [211At]astatide in B6C3F1 and BALB/c (nu/nu) mice: a long-term survival study with histologic analysis. (1996) (21)
- Radioiodination of a monoclonal antibody using N-succinimidyl 5-iodo-3-pyridinecarboxylate. (1993) (21)
- Labeling proteins using aryl iodide acylation agents: influence of meta vs para substitution on in vivo stability. (1989) (21)
- Comparison of the Hypoxia PET Tracer 18F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models (2014) (20)
- Radiolocalization of human pancreatic tumors in athymic mice by monoclonal antibody DU-PAN 1. (1990) (20)
- Radioiodination and astatination of octreotide by conjugation labeling. (2000) (20)
- Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent. (2004) (20)
- Immunoreactivity, pharmacokinetics and bone marrow dosimetry of intrathecal radioimmunoconjugates (1992) (19)
- Synthesis and evaluation of 4-[18F]fluoropropoxy-3-iodobenzylguanidine ([18F]FPOIBG): A novel 18F-labeled analogue of MIBG. (2015) (19)
- Modular nanotransporters for targeted intracellular delivery of drugs: folate receptors as potential targets. (2015) (18)
- N-Succinimidyl 3-((4-(4-[(18)F]fluorobutyl)-1H-1,2,3-triazol-1-yl)methyl)-5-(guanidinomethyl)benzoate ([(18)F]SFBTMGMB): a residualizing label for (18)F-labeling of internalizing biomolecules. (2016) (18)
- Propargyl 4-[18F]fluorobenzoate: A Putatively More Stable Prosthetic group for the Fluorine-18 Labeling of Biomolecules via Click Chemistry (2009) (18)
- Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent. (1998) (18)
- Exposure of human osteosarcoma and bone marrow cells to tumour-targeted α-particles and γ-irradiation: analysis of cell survival and microdosimetry (2000) (18)
- Synthesis, purification, and in vitro stability of 211At- and 125I-labeled amidobisphosphonates. (1999) (18)
- Mouse/human chimeric Me1-14 antibody: genomic cloning of the variable region genes, linkage to human constant region genes, expression, and characterization. (1994) (18)
- Positron emission tomography for the evaluation of pancreatic disease. (1980) (18)
- A tin precursor for the synthesis of no‐carrier‐added [*I]MIBG and [211At]MABG (2007) (18)
- No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog. (1997) (18)
- Cytotoxicity of alpha-particle-emitting 5-[211At]astato-2'-deoxyuridine in human cancer cells. (1997) (18)
- Brush border enzyme-cleavable linkers: Evaluation for reducing renal uptake of radiolabeled prostate-specific membrane antigen inhibitors. (2018) (17)
- Evaluation of an anti-p185(HER2) (scFv-C(H)2-C(H)3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEEK. (2009) (17)
- Cloning and sequencing of V genes from anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: location of lysine residues and implications for radiolabeling. (1995) (17)
- Localization of fluorine-18-labeled Mel-14 monoclonal antibody F(ab')2 fragment in a subcutaneous xenograft model. (1992) (17)
- Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance. (2006) (17)
- Labeling Single Domain Antibody Fragments with Fluorine-18 Using 2,3,5,6-Tetrafluorophenyl 6-[18F]Fluoronicotinate Resulting in High Tumor-to-Kidney Ratios. (2018) (17)
- Production, purification and availability of 211At: Near term steps towards global access. (2021) (17)
- Delivery systems exploiting natural cell transport processes of macromolecules for intracellular targeting of Auger electron emitters. (2019) (17)
- Non-invasive sensitive brain tumor detection using dual-modality bioimaging nanoprobe (2019) (17)
- N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: influence of isomeric substitution on radiolabeling and target cell residualization. (2014) (17)
- Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors. (2018) (16)
- Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2. (2000) (16)
- Carrier‐free 131I‐meta‐iodobenzylguanidine: comparison of production from meta‐diazobenzylguanidine and from meta‐trimethylsilylbenzylguanidine (1994) (16)
- Labeling monoclonal antibodies with halogen nuclides. (1990) (16)
- Radioiodination of proteins using N-succinimidyl 4-hydroxy-3-iodobenzoate. (1993) (16)
- Cytotoxicity of alpha-particle-emitting astatine-211-labelled antibody in tumour spheroids: no effect of hyperthermia. (1998) (16)
- Positively charged templates for labeling internalizing antibodies: comparison of N-succinimidyl 5-iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR. (2001) (16)
- Fluorine-18-antimyosin monoclonal antibody fragments: preliminary investigations in a canine myocardial infarct model. (1992) (16)
- Growth factor receptors as molecular targets for cancer diagnosis and therapy. (1997) (15)
- Abundant tyrosine residues in the antigen binding site in anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: Application to radiolabeling. (1996) (15)
- Synthesis of ring- and side-chain-substituted m-iodobenzylguanidine analogues. (2001) (15)
- A simplified synthesis of the hypoxia imaging agent 2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-[(18)F]pentafluoropropyl)-acetamide ([18F]EF5). (2011) (15)
- Human/murine chimeric 81C6 F(ab')(2) fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma. (2004) (15)
- Two Approaches for Enhancing Radioimmunotherapy: ∝ Emitters and Hyperthermia (1996) (15)
- Preclinical evaluation and PET imaging of 18F-labeled Mel-14 F(ab')2 fragment in normal dogs. (1994) (15)
- Localisation of [131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effect of specific activity. (1996) (14)
- Radiolabeled Antibodies for Tumor Imaging and Therapy (2005) (14)
- Characterization of liposomes containing iodine-125-labeled radiographic contrast agents. (1987) (14)
- Radiolabeled Antibodies for Therapy of Brain Tumors (2001) (14)
- K--L x-ray angular correlations in Cm, Pu, and Eu (1974) (13)
- Evaluation of an internal cyclotron target for the production of 211At via the 209Bi (alpha,2n)211 at reaction. (1996) (13)
- 3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells. (1997) (13)
- A model for optimizing delivery of targeted radionuclide therapies into resection cavity margins for the treatment of primary brain cancers (2017) (13)
- SIB-DOTA: a trifunctional prosthetic group potentially amenable for multi-modal labeling that enhances tumor uptake of internalizing monoclonal antibodies. (2012) (13)
- Method for radioiodination of proteins using N-succinimidyl 3-hydroxy-4-iodobenzoate. (1997) (12)
- Biological evaluation of ring- and side-chain-substituted m-iodobenzylguanidine analogues. (2001) (12)
- Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs. (2016) (12)
- Enhanced tumour uptake of radiolabelled antibodies by hyperthermia. Part II: Application of the thermal equivalency equation (2005) (12)
- Heterogeneity and vascular permeability of breast cancer brain metastases. (2020) (12)
- National Cancer Institute workshop statement: Advances in clinical imaging using positron emission tomography, September 14-16, 1988 (1990) (12)
- Studies of tumor metabolism--II. Mössbauer spectroscopy of 57Co-bleomycin. (1977) (12)
- An Improved 211At-Labeled Agent for PSMA-Targeted α-Therapy (2021) (12)
- Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects. (2007) (12)
- Preparation and characterization of anti-tenascin monoclonal antibody-streptavidin conjugates for pretargeting applications. (1999) (11)
- Synthesis and Evaluation of a 18F-Labeled Triazinediamine Analogue for Imaging Mutant IDH1 Expression in Gliomas by PET. (2018) (11)
- Influence of circulating antigen on blood pool activity of a radioiodinated monoclonal antibody. (1988) (11)
- No-Carrier-Added Astatination of N-Succinimidyl-3-(Tri-n-Butylstannyl) Benzoate (ATE) Via Electrophilic Destannylation (1989) (11)
- A radioiodinated MIBG-octreotate conjugate exhibiting enhanced uptake and retention in SSTR2-expressing tumor cells. (2007) (11)
- Cytotoxicity of alpha-particle-emitting m-[211At]astatobenzylguanidine on human neuroblastoma cells. (1994) (11)
- Radiopharmaceutical chemistry of targeted radiotherapeutics, part 4: Strategies for 211At labeling at high activities and radiation doses of 211At α-particles. (2017) (11)
- Exposure of human osteosarcoma and bone marrow cells to tumour-targeted alpha-particles and gamma-irradiation: analysis of cell survival and microdosimetry. (2000) (11)
- Use of liposomes as carriers for radiation synovectomy. (1988) (11)
- Stability and in vivo behavior of Rh[16aneS4-diol]211 at complex: a potential precursor for astatine radiopharmaceuticals. (2015) (11)
- Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer (2019) (11)
- No-carrier-added synthesis of a 4-methyl-substituted meta-iodobenzylguanidine analogue. (2005) (11)
- Radioimmunotherapy of Cancer (2003) (11)
- Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats (2016) (11)
- D-Amino acid peptide residualizing agents bearing N-hydroxysuccinimido- and maleimido-functional groups and their application for trastuzumab radioiodination. (2015) (11)
- The effects of clinically relevant hyperthermic temperatures on the kinetic binding parameters of a monoclonal antibody. (1996) (11)
- Radioiodinated ganglioside GM1: a potential tool for the investigation of ganglioside function in vivo. (1985) (11)
- A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells (2004) (10)
- Targeting aldehyde dehydrogenase: a potential approach for cell labeling. (2009) (10)
- Effect of radioiodination on the binding of monoclonal antibody DF3 to breast carcinoma cells. (1988) (10)
- 5-[211 At]astato-2'-deoxyuridine, an alpha particle-emitting endoradiotherapeutic agent undergoing DNA incorporation. (1996) (10)
- Radioiodinated O(6)-Benzylguanine derivatives containing an azido function. (2011) (10)
- Preparation and biological evaluation of an astatine-211 labeled biotin conjugate: Biotinyl-3-[211At]astatoanilide (1997) (10)
- Para-[18F]fluorobenzylguanidine kinetics in a canine coronary artery occlusion model (1996) (10)
- Properties of multilamellar liposomes containing 99mTcO4-: effect of distearoylphosphatidylcholine to sphingomyelin ratio. (1986) (9)
- Synthesis of N-succinimidyl-2,4-dimethoxy-3-(tri-N-butylstannyl) benzoate via regio-specifically generated lithium 2,4-dimethoxy-3-lithiobenzoate (1988) (9)
- Meta-iodobenzylguanidine derivatives containing a second guanidine moiety. (2004) (9)
- 4-Fluorobenzylamine and phenylalanine methyl ester conjugates of 2-nitroimidazole: evaluation as hypoxic cell radiosensitizers. (1992) (9)
- [Lu]-DOTA-Tyr-octreotate: A Potential Targeted Radiotherapeutic for the Treatment of Medulloblastoma. (2010) (9)
- Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma. (2005) (9)
- Therapeutic application of dysprosium-165-FHMA in the treatment of rheumatoid knee effusions (1986) (9)
- Site-specific radioiodination of an anti-HER2 single domain antibody fragment with a residualizing prosthetic agent. (2020) (9)
- Evaluation of an 131I-labeled HER2-specific single domain antibody fragment for the radiopharmaceutical therapy of HER2-expressing cancers (2022) (8)
- The effects of local hyperthermia on the catabolism of a radioiodinated chimeric monoclonal antibody. (1998) (8)
- Effects of specific activity on meta-[(131)I]iodobenzylguanidine kinetics in isolated rat heart. (1998) (8)
- Radiohalogenation of Antibodies: Chemical Aspects (1988) (8)
- No-carrier-added (4-fluoro-3-[131I]iodobenzyl)guanidine and (3-[211At]astato-4-fluorobenzyl)guanidine. (1996) (8)
- Monoclonal antibody F(ab')2 fragment labeled with N-succinimidyl 2,4-dimethoxy-3-halobenzoates: in vivo comparison of iodinated and astatinated fragments. (1994) (8)
- Synthesis of 11C-dl-tryptophan and its purification using high-pressure liquid chromatography☆ (1981) (8)
- Preparation and preliminary evaluation of 4-[211At]astato-N-piperidinoethyl benzamide. (1995) (7)
- Meta-[131I]iodobenzylguanidine uptake andmeta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines (2005) (7)
- On-line determination of transport time of a helium-jet system (1974) (7)
- RADIOTOXICITY TO NEUROBLASTOMA CELLS AND SPHEROIDS OF ETA-, ALPHA- AND AUGER ELECTRON- EMITTING CONJUGAYES OFBENZYLGUANIDINE (1998) (7)
- Radiolabelling of glucose-Tyr3-octreotate with 125I and analysis of its metabolism in rats: comparison with radiolabelled DOTA-Tyr3-octreotate. (2007) (7)
- Specific Imaging of Human Brain Tumor Xenografts Utilizing Radiolabelled Monoclonal Antibodies (MAbs) (1986) (7)
- Synthesis and Preliminary Evaluation of 5-[18F]fluoroleucine. (2017) (7)
- O6-3-[131I]iodobenzylguanine: improved synthesis and further evaluation of a potential agent for imaging of alkylguanine-DNA alkyltransferase. (2004) (6)
- Wet harvesting of no-carrier-added 211At from an irradiated 209Bi target for radiopharmaceutical applications (2005) (6)
- d-Amino Acid Peptide Residualizing Agents for Protein Radioiodination: Effect of Aspartate for Glutamate Substitution (2018) (6)
- Abstract 4213: Gold nanostar as theranostic probe for brain tumor sensitive PET-optical imaging and image-guided specific photothermal therapy (2016) (6)
- Evaluation of indium-111 chloride as a radiopharmaceutical for joint imaging in a rabbit model of arthritis. (1987) (6)
- Structure of N=81 nuclei: Levels of 141 Nd and 139 Ce populated in beta decay (1976) (5)
- Detection of amino-terminal extracellular domain of somatostatin receptor 2 by specific monoclonal antibodies and quantification of receptor density in medulloblastoma. (2009) (5)
- Iodopyridine-for-iodobenzene substitution for use with low molecular weight radiopharmaceuticals: application to m-iodobenzylguanidine. (1998) (5)
- The biological behavior of tin following administration of nine 99mTc-Sn complexes. (1977) (5)
- Synthesis and preliminary evaluation of 211At-labeled inhibitors of prostate-specific membrane antigen for targeted alpha particle therapy of prostate cancer. (2021) (5)
- An Improved Method for the Radiohalogenation of Monoclonal Antibodies (1987) (5)
- Two approaches for enhancing radioimmunotherapy: alpha emitters and hyperthermia. (1996) (5)
- A New Route to Guanidines from Bromoalkanes. (1997) (5)
- Use of radiolabeled monoclonal anti-B1 antibody for B lymphocyte imaging in rhesus monkeys. (1987) (5)
- New MIBG preparation to improve targeted radiotherapy and reduce toxic side-effects in neuroblastoma patients undergoing combination treatment. (1995) (5)
- Pharmacokinetics of a radioiodinated monoclonal antibody F(ab')2 fragment in a xenograft model with circulating antigen. (1989) (4)
- Labeling Monoclonal Antibody with α-emitting 211At at High Activity Levels via a Tin Precursor. (2020) (4)
- Labeling a TCO-functionalized single domain antibody fragment with 18F via inverse electron demand Diels Alder cycloaddition using a fluoronicotinyl moiety-bearing tetrazine derivative. (2020) (4)
- Distribution and mechanism of uptake of 111InCl3 in a tumor model for lymph node metastases. (1985) (4)
- Hyperthermic modulation of radiolabeled antibody (mab) uptake in tumors and normal tissues (1992) (4)
- Radiohalogens for Radioimmunotherapy (2000) (4)
- Catabolism of 4-fluoro-3-iodobenzylguanidine and meta-iodobenzylguanidine by SK-N-SH neuroblastoma cells (2004) (4)
- Propargyl 4-[F]fluorobenzoate: A Putatively More Stable Prosthetic group for the Fluorine-18 Labeling of Biomolecules via Click Chemistry. (2009) (4)
- The Radiopharmaceutical Chemistry of the Radioisotopes of Iodine (2019) (4)
- Phase 1 trial study of 131 I-labeled chimeric 81 C 6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma (2004) (4)
- Labeling single domain antibody fragments with 18F using a novel residualizing prosthetic agent - N-succinimidyl 3-(1-(2-(2-(2-(2-[18F]fluoroethoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)-5-(guanidinomethyl)benzoate. (2021) (3)
- Organ distribution of 99mTc-labelled aminethiols. (1977) (3)
- Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose 211At-Labeled Anti-HER2 Single-Domain Antibody Fragment (2022) (3)
- O6-3-[125I]iodobenzyl-2'-deoxyguanosine ([125I]IBdG): synthesis and evaluation of its usefulness as an agent for quantification of alkylguanine-DNA alkyltransferase (AGT). (2005) (3)
- Fluorine-18 Labeling of the MDM2 Inhibitor RG7388 for PET Imaging: Chemistry and Preliminary Evaluation. (2021) (3)
- Experimental determination of the L$sub 2$--L$sub 3$X Coster--Kronig transition probability in europium, plutonium, and curium (1975) (3)
- Monoclonal antibodies to tissue-associated antigens as antitumor reagents. (1984) (3)
- Measurement of the angular correlation between L-M X-ray cascades (1974) (3)
- Observations on the Effects of Residualization and Dehalogenation on the Utility of N-Succinimidyl Ester Acylation Agents for Radioiodination of the Internalizing Antibody Trastuzumab (2019) (3)
- Feasibility of Developing Radiotracers for MDM2: Synthesis and Preliminary Evaluation of an 18F-Labeled Analogue of the MDM2 Inhibitor SP-141 (2021) (2)
- [211At]YC-I-27 for PSMA-Targeted Alpha-Particle Radiopharmaceutical Therapy (2016) (2)
- 125 I-labeled Anti-Epidermal Growth Factor Receptor-vIII Single-Chain Fv Exhibits Specific and High-Level Targeting of Glioma Xenografts 1 (1999) (2)
- Iodination and astatination of antibodies using bifunctional aryltin intermediates (1989) (2)
- Synthesis of carrier-free 131I-meta-iodobenzyl-guanidine by novel routes to enhance therapeutic efficiency in neuroblastoma. (1994) (2)
- RADIOLABELED MONOCLONAL ANTIBODIES (1991) (2)
- Preparation and biological evaluation of an astatine-211 labeled biotin conjugate: biotinyl-3-[211 At]astatoanilide. (1997) (2)
- Site-Specific and Residualizing Linker for 18F Labeling with Enhanced Renal Clearance: Application to an Anti-HER2 Single-Domain Antibody Fragment (2021) (2)
- Decay of 5.8-min ^{140}Pm^{m} and 10-sec ^{140}Pm^{g} to levels of ^{140}Nd (1975) (2)
- Long Term Response in a Patient with Neoplastic Meningitis Secondary to Melanoma Treated with 131 I-Radiolabeled Antichondroitin Proteoglycan (2001) (2)
- Receptor-mediated radiopharmaceuticals (1984) (2)
- Ring-and side-chain-substituted MIBG analogues (2001) (2)
- Preclinical Evaluation of 18 F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by ImmunoPET (2016) (2)
- An astatine-211 labeled PSMA inhibitor for targeted alpha-particle radiotherapy of prostate carcinoma (2009) (2)
- An alternative and expedient synthesis of radioiodinated 4-iodophenylalanine. (2011) (2)
- Search for an anisotropy betweenLlx rays andγrays in the decay ofCm243 (1975) (2)
- Brachytherapy via a depot of biopolymer-bound 131I synergizes with nanoparticle paclitaxel in therapy-resistant pancreatic tumours (2022) (1)
- Molecular imaging of alkylguanine-DNA alkyltransferase: further evaluation of radioiodinated derivatives of O6-benzylguanine. (2006) (1)
- Site-Specific Radiohalogenation of a HER2-Targeted Single-Domain Antibody Fragment Using a Novel Residualizing Prosthetic Agent. (2022) (1)
- Gold Nanostars: A Novel Platform for Developing 211At-Labeled Agents for Targeted Alpha-Particle Therapy (2021) (1)
- Angular correlation between K and L x rays in tantalum (1975) (1)
- Erratum: Cloning and sequencing of V genes from anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: Location of lysine residues and implications for radiolabeling (Nuclear Medicine and Biology (1995) 22 (765- 771)) (1999) (1)
- P19 10 MP – RADIOIMMUNOIHERAPY OF LEPTOMENINGEAL TUMOR USING AT-211 MONOCLONAL ANTIBODY (1991) (1)
- Results of a phase II trial with iodine 131-labeled murine antitenascin monoclonal antibody 81C6 (m81C6) via surgically created resection cavities in the treatment of patients with recurrent malignant brain tumors (2004) (1)
- Local hyperthermia at 420c enhances monoclonal antibody fragment uptake in tumor (1989) (1)
- Abstract 5306: 18F-EF5 microPET imaging of treatment response from a novel, hypoxia-selective cytotoxin SN30000 in a human lung cancer xenograft model (2011) (1)
- Diagnosis and Therapy of Brain Tumors Utilizing Radiolabeled Monoclonal Antibodies (1991) (1)
- Angular correlation of x rays: L − M cascades of plutonium (1975) (1)
- Antibodies for Clinical Use (2001) (1)
- Engineered modular transporters: An approach for targeted alpha particle radiotherapy (2007) (1)
- Targeted Radiotherapy of Central Nervous System Malignancies (2010) (1)
- Tethered Hsp90 Inhibitors Carrying Optical or Radioiodinated Probes Reveal Selective Internalization of Ectopic Hsp90 in Malignant Breast Tumor Cells (2013) (1)
- Synthesis and preliminary evaluation of 5-[18F]fluoroleucine: a novel LAT1 substrate (2016) (1)
- Development of Tethered Hsp90 Inhibitors Carrying Radioiodinated Probes to Specifically Discriminate and Kill Malignant Breast Tumor Cells (2016) (1)
- Comparison of techniques for the determination of the L_{2}-L_{3}X Coster-Kronig transition probability (1975) (1)
- Preclinical 131 I-labeled Anti-HER 2 Camelid sdAb as a Theranostic Tool in Cancer Treatment (2017) (1)
- Application of Small-Scale (Sub-Organ and Cellular Level) Alpha-Particle Specific Dosimetry Model in Tumors and Kidneys in a Pre-Clinical Model of Metastatic Prostate Cancer Using 211At-YC-I-27, a PSMA-Targeting Ligand for Metastatic Prostate Cancer (2016) (1)
- Radioiodination of DF3 antibody: Optimization using in vitro binding assays (1986) (1)
- Genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells from men with metastatic castration resistant prostate cancer (mCRPC) treated with radium-223. (2018) (1)
- Methods for the Radiohalogenation of Antibodies (1991) (1)
- 383 TARGETED ALPHA THERAPY (2012) (1)
- Targeted drug delivery to solid tumors using thermally responsive elastin-like polypeptide macromolecular drug carriers (2006) (1)
- ASTATINE-211 RADIOCHEMISTRY: THE DEVELOPMENT OF METHODOLOGIES FOR HIGH ACTIVITY LEVEL RADIOSYNTHESIS (2012) (0)
- Immunotoxins and Radionuclide Conjugates for Inhibiting Growth of Ovarian and Breast Cancer Cells That Overexpress HER-2 1 (2000) (0)
- Abstract 1809: Next-generation brachytherapy: a preclinical study of a thermally stabilized biopolymer gel for delivering intratumoral radionuclide therapy in a pancreatic tumor mouse model (2015) (0)
- Recombinant antibody-based molecular therapeutics for brain tumor immunotherapy (2007) (0)
- Enhancement of targeted radiotherapy in neuroblastoma: A novel gene therapy approach (2004) (0)
- RECOMBINANT ANTI-TENASCIN ANTIBODY CONSTRUCTS Final Progress Report For the Period 5 / 1 / 1995-11 / 30 / 2005 (2006) (0)
- Radioiodinated AGI-5198 for in vivo imaging of isocitrate dehydrogenase 1 (IDH1) mutation in gliomas (2014) (0)
- Lymphoma treatment with the monoclonal anti-tenascin-antibody (2001) (0)
- Positron emission tomographic imaging of tumors using monoclonal antibodies. Progress report, November 1, 1992--October 31, 1993 (1993) (0)
- Targeted Radiotherapy with Alpha-Particle Emitting Radionuclides Seminar, November 18, 2004, Cracow, Poland. (2004) (0)
- Fluorine-18-LabeledMonoclonalAntibody Fragments:A PotentialApproachfor Combining Radioimmunoscintigraphy and PositronEmission (1992) (0)
- The Synthesis and Biodistribution of a Radioiodinated G M1 Ganglioside Derivative (1986) (0)
- Small Molecule Radiohalogenated (125I/211At), DOTA Containing PSMA Inhibitors: Metal Complexation and Competing Inhibitor Improve Biodistribution in Mice. (2018) (0)
- 211At-Labeled Small-Molecule PSMA Inhibitors: Effect of Structure on Biodistribution in Mice (2016) (0)
- Abstract 4583: In situ photocontrolled intratumoral depot for combined photodynamic therapy and brachytherapy for solid tumor (2014) (0)
- Stapled peptides as scaffolds for developing radiotracers for intracellular targets: preliminary evaluation of a radioiodinated MDM2-binding stapled peptide in the SJSA-1 osteosarcoma model. (2022) (0)
- Abstracts for the Tenth International Conference on Brain Tumour Research and Therapy (2005) (0)
- Angular correlations of x rays: K--L x-ray cascades in $sup 239$Pu . (1973) (0)
- Comparison of the ate and bolton hunter bh methods for radioiodination of monoclonal antibodies mabs (1990) (0)
- Development of an Injectable Brachytherapy Using Self-Assembly Polypeptides (2016) (0)
- Radioconjugacion internalizing antibody. (1999) (0)
- 296 Trastuzumab monoclonal antibody labeled with alpha-particle emitter astatine: targeted radiotherapeutic experiments on a HER2-positive breast carcinomatous meningitis animal model after intrathecal administration (2004) (0)
- Modular nanotransporters efficiently deliver Auger electron emitters into nuclei of cancer сells (2013) (0)
- Low Level Whole-Brain Radiation Enhances Theranostic Potential Of Single Domain Antibody Fragments For HER2-Positive Brain Metastases (2022) (0)
- Therapy with Drug-Monoclonal Antibody Conjugates (2003) (0)
- Low-level whole-brain radiation enhances theranostic potential of single-domain antibody fragments for human epidermal growth factor receptor type 2 (HER2)-positive brain metastases (2022) (0)
- Abstract 5831: Biopolymer β-brachytherapy delivered concomitantly with systemic paclitaxel outperforms traditional x-ray radiation to induce complete regression in multiple pancreatic tumor xenograft models (2018) (0)
- The Applications of Monoclonal Antibodies in Neuro-Oncology (1987) (0)
- Propargyl 4-[F-18]fluorobenzoate: A putatively more stable prosthetic group for the F-18 labeling of biomolecules via click chemistry (2008) (0)
- Modular nanotransporters: A flexible platform forward for targeted Auger electron therapy (2012) (0)
- Synergistic Interaction between Anti-p 185 HER-2 Ricin A Chain Immunotoxins and Radionuclide Conjugates for Inhibiting Growth of Ovarian and Breast Cancer Cells That Overexpress HER-21 (2000) (0)
- Abstract 5615: Evaluation of the antitumoral efficacy and toxicity of injectable, polymeric radionuclide seeds in a noninvasive preclinical prostate tumor model. (2013) (0)
- Weighted Summation of Oxygen-15-Water PET Data to Increase Signal-to-Noise Ratio for Activation Studies (1997) (0)
- Decay of 5.8-min $sup 140$Pm/subm/ and 10-sec $sup 140$Pm/subg/ to levels of $sup 140$Nd (1975) (0)
- Site-specific radiolabeling of an anti-HER2 single domain antibody fragment with an 211At-labeled prosthetic agent: preliminary evaluation of a potential targeted α-particle therapeutic (2022) (0)
- Glycated octreotide and octreotate analogues for specific and high-level targeting to medulloblastoma (2001) (0)
- Biokinetics of a radioiodinated antibreast carcinoma monoclonal antibody and fragment in humans (1984) (0)
- 115 A radioiodinated meta-iodobenzylguanidine-octreotate conjugate (2004) (0)
- Optimization of an antibreast carcinoma monoclonal antibody as a tumor imaging agent (1984) (0)
- mCi/mg by this technique without loss of immunoreactivefraction (2006) (0)
- Synthesis and Preliminary Evaluation of 5-[ 18 F ] fluoroleucine (2017) (0)
- Abstract C86: Tethered Hsp90 inhibitors carrying optical or radioiodinated probes reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells. (2013) (0)
- Dosimetry of 1311-Labeled81C6 Monoclonal Antibody Administered into Surgically Created Resection Cavities in Patients with Malignant Brain Tumors (2006) (0)
- Development and radiotherapeutic application of /sup 211/At-labeled radiopharmaceuticals. Progress report, March 1, 1981-February 28, 1982 (1981) (0)
- the Hypoxia-Activated Prodrug SN30000 Combined with Radiation Treatment in a Non-Small Cell Lung Cancer Xenograft Model (2013) (0)
- Therapy with Unmodified Monoclonal Antibodies (2003) (0)
- Abstract 2884: Preclinical studies on tumor retention, antitumor efficacy and toxicity of thermally responsive polypeptide-based radionuclide intratumoral depot in nude mice (2012) (0)
- Synthesis of N-Succinimidyl-2,4-dimethoxy-3-(tri-N-butylstannyl)benzoate via Regiospecifically Generated Lithium 2,4-Dimethoxy-3-lithiobenzoate. (1989) (0)
- Barriers to Successful Serotherapy (2003) (0)
- BRAIN IMAGING WITH THE SEARLE TWO-CAMERA SYSTEM (1978) (0)
- Monoclonal Antibodies against EGFRvIII Are Tumor Specific and React with Breast and Lung Carcinomas and Malignant ( Â ¿ liornas 1 (2006) (0)
- Positron emission tomographic imaging of tumors using monoclonal antibodies. Progress report, April 15, 1992--October 31, 1992 (1992) (0)
- Positron emission tomographic imaging of tumors using monoclonal antibodies (1992) (0)
- Production of Astatine-211 at the Duke University Medical Center for its regional distribution (2016) (0)
- Biodistribution of a labeled monoclonal antibody to B lymphocytes (1985) (0)
- Radioactive Noble Gases for Medical Applications (2019) (0)
- Comparative Tissue Distribution in Mice of the «-Emitter211Atand of a Monoclonal Antibody and F(ab')2 Fragment1 (2006) (0)
- Stabilized compositions and methods for radiolabeling the drug with alpha-partikelemittere (2006) (0)
- Recombinant Anti-Tenascin Antibody Contructs (2006) (0)
- Abstract 4341: A novel injectable polymer liquid that self-assembles into radioactive “seeds” for brachytherapy. (2013) (0)
- 196 OPTIMIZATION OF CONTRAST-CARRYING LIPOSOMES (1985) (0)
- Search for an anisotropy between Ll x rays and $gamma$ rays in the decay of $sup 243$Cm (1975) (0)
- Current BER Scientists: Principal Investigators (2001) (0)
- Radiohalogenation of monoclonal antibodies (1986) (0)
- Simplified 211At-labeling of internalizing proteins by preconjugation with the tin precursor of a residualizing prosthetic agent: Application to an anti-HER2 single domain antibody fragment (2018) (0)
- 22 Monoclonal Antibodies (0)
- Radioiodinated ganglioside G/sub M1/: A potential tracer for neurological studies (1985) (0)
- Reply: Pharmacokinetic and Pharmacodynamic Modifiers of EF5 Uptake and Binding (2015) (0)
- Positron tomographic imaging of tumors using monoclonal antibodies. Final progress report, April 15, 1989--October 31, 1995 (1997) (0)
- Abstract B48: Preclinical development of meta-[211At] astatobenzylguanidine ([211At] MABG) targeted radiotherapy for neuroblastoma (2014) (0)
- Radiolabeled Monoclonal Antibodies and Hyperthermia. Final Progress Report for November 1, 1998 - April 30, 2003 (2004) (0)
- Calcium absorption, vitamin D status and bone disease after bowel resection for Crohn's disease. (1980) (0)
- Modular nanotransporters: a chimeric multi-functional platform for drug delivery in vivo (2010) (0)
- Abstract #1254: Podoplanin is a novel antibody-based therapeutic target for glioblastoma (2009) (0)
- 283 Targeting of human glioma xenografts with an anti-EGFRvIII minibody (MR1-1scFv-CH3) (2004) (0)
- The Angular Correlations of X Rays: K-L X-ray Cascades in 239 Pu (1973) (0)
- Invited oral presentations (1997) (0)
- Abstract 5485: Modular nanotransporters: a chimeric multi-functional platform for drug deliveryin vivo (2010) (0)
- Quantitative measurements of cerebral metabolism with the searle positron camera (1978) (0)
- Elimination of Malignant Cells from Bone Marrow Ex Vivo (2003) (0)
- N‐Succinimidyl 5‐(Trialkylstannyl)‐3‐pyridinecarboxylates: A New Class of Reagents for Protein Radioiodination. (2010) (0)
- Receptor Based Radiopharmaceuticals (1985) (0)
- Oral Presentations 6 (2004) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Michael R. Zalutsky?
Michael R. Zalutsky is affiliated with the following schools:
